ATTAIN-1 (NCT05869903) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes
This guide covers both routes side by side so the math, supplies, and evidence boundaries stay separate instead of blurring together
The cell pellets were thawed and lysed in a buffer containing 20 mM HEPES, pH 7.5, 100 mM NaCl, 10% (v/v) glycerol, 10 mM MgCl 2 , 1 mM MnCl 2 and 100 M TCEP supplemented with EDTA-free protease inhibitor cocktail (Bimake) by dounce homogenization
By helping regulate appetite and blood sugar levels, these innovative treatments can support your journey towards achieving a healthier lifestyle